kabutan

Noile-Immune Biotech Inc.(4893) Summary

4893
TSE Growth
Noile-Immune Biotech Inc.
151
JPY
-4
(-2.58%)
Dec 12, 3:30 pm JST
0.96
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
150
Dec 12, 10:17 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.59
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
154 JPY 0.99 USD
Previous Close Dec 11
155 JPY 0.99 USD
High Dec 12, 9:25 am
155 JPY 0.99 USD
Low Dec 12, 2:41 pm
150 JPY 0.96 USD
Volume
70,600
Trading Value
0.01B JPY 0.07M USD
VWAP
151.81 JPY 0.98 USD
Minimum Trading Value
15,100 JPY 96 USD
Market Cap
6.54B JPY 0.04B USD
Number of Trades
96
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
255
1-Year High Jul 2, 2025
8,956
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 140,000 1,030,300 7.36
Nov 28, 2025 333,500 1,079,000 3.24
Nov 21, 2025 343,500 1,119,900 3.26
Nov 14, 2025 395,500 1,144,300 2.89
Nov 7, 2025 420,900 1,132,600 2.69
Company Profile
Noile-Immune Biotech Inc. engages in the development of novel immunotherapies utilizing CAR-T cells for cancer treatment.
Sector
Pharmaceuticals
Noile-Immune Biotech Inc. focuses on developing novel immunotherapies utilizing CAR-T cells for cancer treatment. The company aims to develop effective CAR-T cell therapies for solid tumors using its proprietary PRIME technology. PRIME technology is a platform technology that can be applied to regenerative medicine, with the potential to achieve superior cancer treatment effects by activating immune cells within the patient's body. It promotes the infiltration and activation of immune cells into solid tumor tissues. Noile-Immune Biotech pursues two business models: in-house drug discovery and collaborative pipelines, with multiple pipelines in progress. The company is also conducting clinical trials targeting solid tumors, exploring new possibilities in cancer immunotherapy.